Skip to content
Subscriber Only

Glaxo Takes Aim at Covid-19 in $250 Million Pact With Vir

  • Pharma giant to work with Vir to find coronavirus therapies
  • Glaxo is also collaborating to develop a vaccine, tests
Updated on

U.K. pharmaceutical giant GlaxoSmithKline Plc is joining dozens of companies in the hunt for coronavirus therapies, signing a partnership with Vir Biotechnology Inc. and agreeing to invest $250 million in the U.S. company.

Glaxo and Vir will work together to find experimental antibodies to treat or prevent Covid-19, the illness caused by the coronavirus, the British drugmaker said on Monday. The companies plan to move two candidates straight into mid-stage trials in three to five months, subject to regulatory approval, Glaxo said.